Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 4,167 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $85.78, for a total transaction of $357,445.26. Following the completion of the transaction, the executive vice president now owns 96,471 shares of the company’s stock, valued at approximately $8,275,282.38. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Robert Azelby also recently made the following trade(s):

  • On Monday, January 22nd, Robert Azelby sold 102,539 shares of Juno Therapeutics stock. The shares were sold at an average price of $86.25, for a total transaction of $8,843,988.75.
  • On Wednesday, January 17th, Robert Azelby sold 29,131 shares of Juno Therapeutics stock. The shares were sold at an average price of $68.61, for a total transaction of $1,998,677.91.
  • On Monday, December 18th, Robert Azelby sold 1,816 shares of Juno Therapeutics stock. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36.

Juno Therapeutics Inc (NASDAQ:JUNO) opened at $85.60 on Monday. Juno Therapeutics Inc has a 12-month low of $19.62 and a 12-month high of $86.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77. The firm has a market cap of $9,872.42, a PE ratio of -25.33 and a beta of 3.43.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The company had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same period last year, the company posted ($0.57) earnings per share. The business’s revenue for the quarter was up 115.4% on a year-over-year basis. sell-side analysts expect that Juno Therapeutics Inc will post -4.02 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in JUNO. JPMorgan Chase & Co. boosted its holdings in shares of Juno Therapeutics by 80.3% in the second quarter. JPMorgan Chase & Co. now owns 113,124 shares of the biopharmaceutical company’s stock worth $3,382,000 after buying an additional 50,378 shares during the period. Teachers Advisors LLC boosted its holdings in shares of Juno Therapeutics by 15.4% in the second quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after buying an additional 9,890 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in shares of Juno Therapeutics by 9.0% in the second quarter. TIAA CREF Investment Management LLC now owns 188,481 shares of the biopharmaceutical company’s stock worth $5,634,000 after buying an additional 15,491 shares during the period. BlackRock Inc. boosted its holdings in shares of Juno Therapeutics by 2.6% in the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after buying an additional 110,503 shares during the period. Finally, Amalgamated Bank boosted its holdings in shares of Juno Therapeutics by 19.0% in the second quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 1,741 shares during the period. Institutional investors own 69.32% of the company’s stock.

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. Raymond James Financial reiterated a “buy” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. Wells Fargo & Co reiterated a “market perform” rating and issued a $63.00 target price (up previously from $54.00) on shares of Juno Therapeutics in a research report on Wednesday, January 17th. Barclays lowered shares of Juno Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the company from $55.00 to $87.00 in a research report on Wednesday, January 24th. Finally, Maxim Group restated a “buy” rating and set a $56.00 price objective on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $51.20.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/juno-therapeutics-inc-juno-evp-robert-azelby-sells-4167-shares/1845482.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.